Premium
Fluorescence Detection and Dissociation of Amyloid‐β Species for the Treatment of Alzheimer's Disease
Author(s) -
Lv Guanglei,
Shen Yang,
Zheng Wubin,
Yang Jiajia,
Li Chunxia,
Lin Jun
Publication year - 2019
Publication title -
advanced therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
0ISSN - 2366-3987
DOI - 10.1002/adtp.201900054
Subject(s) - photodynamic therapy , disease , amyloid (mycology) , chemistry , fluorescence , alzheimer's disease , dissociation (chemistry) , neuroscience , amyloid β , medicine , biophysics , biology , pathology , physics , organic chemistry , quantum mechanics
Alzheimer's disease (AD) is one of the most prevalent forms of neurodegenerative disease. It is well established that the β‐amyloid peptide (Aβ) species existing in several forms, such as soluble monomers, oligomers, and insoluble aggregates, play an essential role in the pathophysiology of AD. Therefore, much effort has been made to specifically detect Aβ species and to inhibit Aβ aggregation for the treatment of AD. In this review, an overview of recent advances in detecting different Aβ forms mainly containing Aβ aggregates, Aβ oligomers, and Aβ protofibrils is provided. In addition, photodynamic therapy (PDT) and photothermal therapy (PTT) are considered to be promising modalities for the treatment of AD because of the minimal invasiveness and high spatial selectivity. Herein, the strategies of inhibiting Aβ aggregation and dissociating Aβ aggregates using PDT, PTT, and Aβ inhibitors for the treatment of AD are summarized.